Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that trichoscopy can identify specific patterns in alopecia areata, such as white and black dots, which assists in non-invasive diagnosis and assessing disease severity.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

A certain gene variation can affect protein production and is linked to male pattern baldness.

In this study, the misshaped and hairy ear phenotype in mutant mice was linked to mis-expression of certain Hoxc genes due to a chromosomal inversion.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study concluded that exclamation mark hairs are the most reliable marker of disease activity in alopecia areata, with broken hairs, triangular hairs, and black dots also increasing the probability of active disease.

In this study, a new hairless gene in the Donryu rat strain was identified, showing skin similarities to human skin tumors with multiple follicular cysts.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study suggests that the O'Connor Tweezer Dexterity Test is a valuable tool for screening surgical assistants in hair transplantation for their ability to accurately and quickly place hair-grafts.

This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

In this study, the presence of certain KAP15-1 gene variants in sheep was associated with differences in wool yield and fiber characteristics.

This study found that variation in the ovine KRTAP27-1 gene may influence wool growth, with certain genotypes associated with higher mean staple length and greasy fleece weight in sheep.

In this study, RNA-sequencing identified differentially expressed genes, including FGF5, FGFR1, and RRAS, that affect the hair follicle growth cycle in Inner Mongolian Cashmere goats.

This study observed that the herbal extract WJWE promoted hair growth and protected hair follicle cells in a DHT-induced murine model of androgenetic alopecia, potentially by engaging the SIRT1/JNK/p38 MAPK and Wnt5A/β-Catenin signaling pathways.

The document's conclusion cannot be determined from the provided text.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study evaluated how often racial and ethnic minorities were included in phase II and III randomized controlled trials for androgenetic alopecia conducted in the United States in the past decade, aiming to inform more personalized treatment approaches.

This study reports that Wise is expressed in specific patterns during the morphogenesis of chick embryos, particularly in regions associated with known signaling molecules like Wnt, Bmp, and Shh.

This case report illustrates how SNP array testing helped identify a DCAF17 mutation linked to Woodhouse-Sakati syndrome in consanguineous Qatari siblings with shared features including alopecia and hypogonadotropic hypogonadism.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

The document doesn't provide enough information to summarize.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.